Cited by 1,151Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles, Tan, Daniel S W, Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximillian, Cortot, Alexis B, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G, McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian, de Castro, Gilberto·2017·The Lancet

DOI 10.1016/s0140-6736(17)30123-x

Open this paper in CoChat — free account

Abstract

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m 2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m 2 ] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening. Investigators and patients were not masked to treatment assignment. The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. Findings Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceriti…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30123-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citation
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 867
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Self-citation

Show all 26 references

Sorted by citations

Items 301–400 of 1,000

Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study
Takenaka, T., Yano, T., Yamazaki, K., Okamoto, T., Hamatake, M., Shimokawa, M., & Mori, M. (2022) · JTCVS Open · doi:10.1016/j.xjon.2022.03.004 · Cited by 30
A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts – cardiologists and oncologists
Leszek, P., Klotzka, A., Bartuś, S., Burchardt, P., Czarnecka, A. M., Długosz‐Danecka, M., Gierlotka, M. J., Koseła-Paterczyk, H., Krawczyk‐Ożóg, A., Kubiatowski, T., et al. (2023) · Kardiologia Polska · doi:10.33963/v.kp.96840 · Cited by 31
Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma
Kwok, H., Ning, Z., Chong, P., Wan, T. S. K., Ng, M. H. L., Ho, G. Y. F., Ip, M., & Lam, D. C.-L. (2019) · Cancers · doi:10.3390/cancers11010104 · Cited by 31
GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors
Jiang, J., Wu, X., Tong, X., Wei, W., Chen, A., Wang, X., Shao, Y. W., & Huang, J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.011 · Cited by 29
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
Kauffmann-Guerrero, D. E., Kahnert, K., & Huber, R. M. (2020) · Drugs · doi:10.1007/s40265-020-01445-2 · Cited by 29
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer
Wang, B., Guo, H., Xu, H., Yu, H., Chen, Y., & Zhao, G. (2021) · Cells · doi:10.3390/cells10102620 · Cited by 29
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Marinelli, D., Siringo, M., Metro, G., Ricciuti, B., & Gelibter, A. J. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-1 · Cited by 30
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
Andō, K., Manabe, R., Kishino, Y., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., & Sagara, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032242 · Cited by 29
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Deslypere, G., Gullentops, D., Wauters, E., & Vansteenkiste, J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918772810 · Cited by 29
Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer
Shi, H., Gou, X., Zhang, S., Zhang, X., Huang, H., Wang, W., Yi, L., Zhang, R., Duan, Z., Zhou, P., et al. (2023) · Small Methods · doi:10.1002/smtd.202301127 · Cited by 29
Acquired Resistance in Oncogene-Addicted Non-Small-Cell Lung Cancer
Sini, C., Tuzi, A., Rossi, G., Russo, A., & Pezzuto, A. (2018) · Future Oncology · doi:10.2217/fon-2018-0097 · Cited by 29
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Li, X., Huang, C., Xie, X., Wu, Z., Tian, X., Wu, Y., Du, X., & Shi, L. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13309 · Cited by 28
Self-citation
Salting the Soil: Targeting the Microenvironment of Brain Metastases
Srinivasan, E. S., Tan, A. C., Anders, C. K., Pendergast, A. M., Sipkins, D. A., Ashley, D. M., Fecci, P. E., & Khasraw, M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0579 · Cited by 29
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Calabrese, F., Pezzuto, F., Lunardi, F., Fortarezza, F., Tzorakoleftheraki, S., Resi, M. V., Tinè, M., Pasello, G., & Hofman, P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084164 · Cited by 28
Advancements of ALK inhibition of non-small cell lung cancer: a literature review
Zia, V. A. D. A., Lengyel, C. G., Tajima, C. C., & de Mello, R. A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-619 · Cited by 28
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
Genomic Testing in Lung Cancer: Past, Present, and Future
Mascaux, C., Tsao, M., & Hirsch, F. R. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7019 · Cited by 27
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Ricciuti, B., Giglio, A. D., Mecca, C., Arcuri, C., Marini, S., Metro, G., Baglivo, S., Sidoni, A., Bellezza, G., Crinò, L., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1133-4 · Cited by 27
Self-citation
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer
Li, H., Lai, L., & Wu, B. Y. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00880-8 · Cited by 27
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer
Zhao, B., Han, Y., Wang, Y., Wang, Y., Wang, Y., Xing, H., Dai, C., Wang, Y., Wang, H., & Ma, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105931 · Cited by 27
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
Sun, S. A., Pithavala, Y. K., Martini, J., & Chen, J. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2056 · Cited by 28
Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
Kiełbowski, K., Żychowska, J., & Becht, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285374 · Cited by 28
Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Liu, B., Yuan, M., Sun, Y., Cheng, Z., Zhang, Z., Hou, S., Wang, X., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23840 · Cited by 27
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK -positive non-small-cell lung cancer
Pyo, K., Lim, S. M., Park, C.-W., Jo, H.-N., Kim, J. H., Yun, M., Kim, D., Xin, C.-F., Lee, W., Gheorghiu, B.-I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000970 · Cited by 28
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Sisi, M., Fusaroli, M., Giglio, A. D., Facchinetti, F., Ardizzoni, A., Raschi, E., & Gelsomino, F. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00865-8 · Cited by 27
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Mason, C., Ellis, P. G., Lokay, K., Barry, A., Dickson, N. R., Page, R. D., Polite, B. N., Salgia, R., Savin, M., Shamah, C. J., et al. (2018) · Journal of Clinical Pathways · doi:10.25270/jcp.2018.02.00001 · Cited by 26
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 29
Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Baldacci, S., Besse, B., Avrillon, V., Mennecier, B., Mazières, J., Dubray‐Longeras, P., Cortot, A. B., Descourt, R., Doubre, H., Quantin, X., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.018 · Cited by 27
Self-citation
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
Bylicki, O., Tomasini, P., Gervais, R., Guisier, F., Monnet, I., Ricordel, C., Bigay-Game, L., Geier, M., CHOUAID, C., Daniel, C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.014 · Cited by 26
Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review
Król, K., Mazur, A., Stachyra, P., & Grzybowska‐Szatkowska, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065858 · Cited by 27
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
Rossi, A., Aimar, G., Audisio, M., Bungaro, M., Caglio, A., Liello, R. D., Gamba, T., Gargiulo, P., Ghisoni, E., Lombardi, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.008 · Cited by 27
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule
Rodon, J. A., Gray, N. S., Mok, T. S. K., & Gainor, J. F. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_242209 · Cited by 27
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
Genova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 27
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
Zhao, M., Shao, T., Shao, H., Zhou, C., & Tang, W. (2024) · BMC Cancer · doi:10.1186/s12885-024-11916-4 · Cited by 26
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Barrows, S., Wright, K. R., Copley‐Merriman, C., Kaye, J. A., Chioda, M. D., Wiltshire, R., Torgersen, K. M., & Masters, E. T. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s179349 · Cited by 26
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
Myall, N. J., Lei, A. Q., & Wakelee, H. A. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-564 · Cited by 25
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
Carcereny, E., Fernández-Nistal, A., López, A., Montoto, C., Naves, A., Segú-Vergés, C., Coma, M., Jorba, G., Oliva, B., & Mas, J. M. (2021) · Oncotarget · doi:10.18632/oncotarget.27875 · Cited by 25
Systemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 26
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer
Schmid, S., Cheng, S., Chotai, S., García-Pardo, M., Zhan, L. J., Hueniken, K., Balaratnam, K., Khan, K., Patel, D., Grant, B., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.007 · Cited by 25
New perspectives for targeting therapy in ALK-positive human cancers
Zhao, S., Li, J., Xia, Q., Liu, K., & Dong, Z. (2023) · Oncogene · doi:10.1038/s41388-023-02712-8 · Cited by 25
Advancements in NSCLC
Xu, J., Tian, L., Qi, W., Lv, Q., & Wang, T. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001088 · Cited by 29
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
Yang, C., Liao, W., Ho, C., Chen, K., Tsai, T.-H., Hsu, C., Liu, Y., Su, K., Chang, Y., Wu, C., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0088 · Cited by 25
Self-citation
Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
Singh, A., & Chen, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s260274 · Cited by 25
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
Andraos, E., Dignac, J., & Meggetto, F. (2021) · Cancers · doi:10.3390/cancers13010144 · Cited by 24
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy
Wiesweg, M., Preuß, C., Roeper, J., Metzenmacher, M., Eberhardt, W., Stropiep, U., Wedeken, K., Reis, H., Herold, T., Darwiche, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.036 · Cited by 24
Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
Jablonska, P. A., Bosch‐Barrera, J., Serrano, D., Valiente, M., Calvo, A., & Aristu, J. (2021) · Cancers · doi:10.3390/cancers13092141 · Cited by 24
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
Haratake, N., Toyokawa, G., Seto, T., Tagawa, T., Okamoto, T., Yamazaki, K., Takeo, S., & Mori, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1940964 · Cited by 24
Novel targeted therapies for advanced non-small lung cancer
Abughanimeh, O. K. M., Kaur, A., Osta, B. E. E., & Ganti, A. K. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.03.003 · Cited by 26
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature
Albaba, H., Lim, C. H., & Leighl, N. B. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0563-8 · Cited by 24
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
Yang, J., & Gong, W.-L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1570846 · Cited by 25
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25
Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Li, J., Knoll, S., Bocharova, I., Tang, W., & Signorovitch, J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541443 · Cited by 23
Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Liu, M., Zhang, L., Huang, Q., Li, N., Zheng, B., & Cai, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s223441 · Cited by 23
Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta‐analysis
Peng, Y., Zhao, Q., Liao, Z., Ma, Y., & Ma, D. (2023) · Cancer · doi:10.1002/cncr.34664 · Cited by 23
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer
Sakakibara‐Konishi, J., Kitai, H., Ikezawa, Y., Hatanaka, Y., Sasaki, T., Yoshida, R., Chiba, S., Matsumoto, S., Goto, K., Mizugaki, H., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.021 · Cited by 23
Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Giustini, N., Jeong, A., Buturla, J. A., & Bazhenova, L. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.003 · Cited by 23
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Xia, B., Nagasaka, M., Zhu, V. W., Ou, S. I., & Soo, R. A. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-331 · Cited by 24
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study
Goto, Y., Yamamoto, N., Masters, E. T., Kikkawa, H., Mardekian, J., Wiltshire, R., Togo, K., & Ohe, Y. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01392-0 · Cited by 22
Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model
Wang, J.-L., Lan, Y., Tsai, Y.-T., Chen, Y.-C., Staniczek, T., Tsou, Y., Yen, C., & Chen, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.688062 · Cited by 22
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
Wu, K., Chen, H., Tsai, Y., Lee, T.-H., Chang, H.-M., Tsai, Y.-C., Chuang, C., Chang, Y.-C., Tu, Y., Yang, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194376 · Cited by 22
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal
Chow, R., Lage, D. E., Williams, G. R., Sedrak, M. S., Greer, J. A., Temel, J. S., & Nipp, R. D. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7055 · Cited by 22
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients
Gil, M., Knetki‐Wróblewska, M., Niziński, P., Strzemski, M., & Krawczyk, P. A. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2187077 · Cited by 23
Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer
Kuang, Z., Miao, J., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1327449 · Cited by 23
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions
Qin, A., & Gadgeel, S. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0526-1 · Cited by 22
Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses
Ni, J., Li, G., Yang, X., Chu, L., Wang, J., Li, Y., Zou, L., Li, Y., Xie, C., & Zhu, Z. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1240-1 · Cited by 22
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer
Wang, W., Sun, X. S., & Hui, Z. (2019) · Oncology Research and Treatment · doi:10.1159/000502755 · Cited by 22
Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
Liu, C., Yu, H., Long, Q., Chen, H., Li, Y., Zhao, W., Zhao, K., Zhu, Z., Sun, S., Fan, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01116 · Cited by 22
Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer
Darsa, H. E., Abdel-Rahman, O. M., & Sangha, R. S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774552 · Cited by 22
ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)
Li, M., Hou, X., Chen, J., Zhang, B., Wang, N., Han, H., & Chen, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.006 · Cited by 22
Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy
Cardoso, V. M. D. O., Bistaffa, M. J., Sterman, R. G., de Lima, L. L. P., Toldo, G. S., Cancino‐Bernardi, J., & Zucolotto, V. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c16840 · Cited by 21
Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure
Sonoda, D., Matsuura, Y., Kondo, Y., Ichinose, J., Nakao, M., Ninomiya, H., Ishikawa, Y., Nishio, M., Okumura, S., Satoh, Y., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13669 · Cited by 21
Treatment of brain metastases in ALK-positive non-small cell lung cancer
Ceddia, S., & Codacci-Pisanelli, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103400 · Cited by 23
Meeting an un-MET need: Targeting MET in non-small cell lung cancer
Michaels, E., & Bestvina, C. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004198 · Cited by 22
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
Barbieri, M. A., Sorbara, E. E., Cicala, G., Santoro, V., Cutroneo, P. M., Franchina, T., Santarpía, M., Silvestris, N., & Spina, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005626 · Cited by 21
Optimal Path Planning for Mobile Robots in Complex Environments Based on the Gray Wolf Algorithm and Self-Powered Sensors
Zhang, Q., Zhao, J. H., Pan, L., Wu, X. X., Hou, Y., & Qi, X. (2023) · IEEE Sensors Journal · doi:10.1109/jsen.2023.3252635 · Cited by 21
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
Fabbri, L., Federico, A. D., Astore, M., Marchiori, V., Rejtano, A., Seminerio, R., Gelsomino, F., & Giglio, A. D. (2023) · Diagnostics · doi:10.3390/diagnostics14010048 · Cited by 21
The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer
Gomes, F., Tay, R. Y., Chiramel, J., & Califano, R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0573-z · Cited by 22
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
Heo, J. Y., Park, C., Keam, B., Ock, C., Kim, M., Kim, T. M., Kim, D., Kim, S. H., Kim, Y. J., Lee, J. S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13195 · Cited by 20
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer
Boosman, R. J., Burgers, J. A., Smit, E. F., Steeghs, N., van der Wekken, A. J., Beijnen, J. H., Huitema, A. D. R., & ter Heine, R. (2021) · Drugs · doi:10.1007/s40265-021-01654-3 · Cited by 20
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
Greillier, L., Gauvrit, M., Paillaud, É., Girard, N., Montégut, C., Boulahssass, R., Wislez, M., Pamoukdjian, F., Corre, R., Cabart, M., et al. (2022) · Cancers · doi:10.3390/cancers14030769 · Cited by 20
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis
Tao, Y., Zhou, Y. L., Tang, L. M., Chen, H., Feng, Y., & Shi, Y. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01242-6 · Cited by 20
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
Luo, X., Zhou, Z., Zeng, X., Peng, L., & Liu, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.985834 · Cited by 20
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 20
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
Chazan, G., & Solomon, B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-656 · Cited by 22
Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario
Bertaglia, V., Morelli, A. M., Solinas, C., Aiello, M. M., Manunta, S., Denaro, N., Tampellini, M., Scartozzi, M., & Novello, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103954 · Cited by 20
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
Ndembe, G., Intini, I., Moro, M., Grasselli, C., Panfili, A., Panini, N., Bleve, A., Occhipinti, M. A., Borzi, C., Garassino, M. C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02933-5 · Cited by 22
Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)
Umar, H., Wahab, H. A., Attiq, A., Amjad, M. W., Bukhari, S. N. A., & Ahmad, W. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111856 · Cited by 23
Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer
Califano, R., Greystoke, A., Lal, R., Thompson, J., & Popat, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.004 · Cited by 20
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
Reckamp, K. L., Lin, H. M., Huang, J., Proskorovsky, I., Reichmann, W. M., Krotneva, S., Kerstein, D., Huang, H., & Lee, J. J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1520696 · Cited by 20
Ocular And Orbital Side Effects of Alk Inhibitors: A Review Article
Chelala, E., Hoyek, S., Arej, N., Kattan, J. G., Kourié, H. R., Baakliny, J., & Antoun, J. (2019) · Future Oncology · doi:10.2217/fon-2018-0608 · Cited by 20
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib
Wong, H. H., Bentley, H., Bulusu, V. R., Anyaegbu, G., Watkins, J. A., Horan, G., & Hatcher, H. M. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000994 · Cited by 20
Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma
Cai, L., Wang, J., Yan, J., Zeng, J., Zhu, L., Liang, J., Pan, C., Huang, X., Jin, J., Xu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.603671 · Cited by 20
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States
Zhou, Z., Mutebi, A., Han, S., Bensimon, A. G., Ricculli, M. L., Xie, J., Dalal, A. A., & Culver, K. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1443111 · Cited by 20
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors
Hurtado, F. K., de Braud, F., de Castro, J., Miguel, M. J. D., Wang, D., Scott, J. W., Lau, Y. Y., McCulloch, T., & Mau‐Sørensen, M. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04180-3 · Cited by 19
Self-citation
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies
Bourreau, C., Treps, L., Faure, S., Fradin, D., & Clere, N. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108347 · Cited by 20
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 21

Authors: Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., Hochmair, M., Cortot, A. B., Tsai, C.-M., Moro-Sibilot, D., Campelo, R. G., McCulloch, T., Sen, P., Dugan, M., Pantano, S., Branle, F., Massacesi, C., & de Castro, G.
Affiliations: Université Paris-Sud (FR)
National Cancer Centre Singapore (SG)
Azienda Ospedaliera di Perugia (IT)
Guangdong General Hospital (CN)
Universidad Complutense de Madrid (ES)
University Hospital Cologne (DE)
Songklanagarind Hospital (TH)
Azienda Ospedaliera San Gerardo (IT)
National Taiwan University Hospital (TW)
Otto Wagner Hospital (AT)
Centre Hospitalier Universitaire de Lille (FR)
Taipei Veterans General Hospital (TW)
Universidade da Coruña (ES)
Novartis (Switzerland) (CH)
Corresponding author: Soria, Jean-Charles
ORCID: Soria, Jean-Charles
Tan, Daniel S W
Chiari, Rita
Wu, Yi-Long
Paz-Ares, Luis
Geater, Sarayut L
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximillian
Cortot, Alexis B
Tsai, Chun-Ming
Campelo, Rosario G
Branle, Fabrice
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-03
Volume: 389
Issue: 10072
Pages: 917-929
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30123-x
OpenAlex: W2581996620
Cited by: 1,151
References: 26
Citations by year: 2026: 38 · 2025: 73 · 2024: 98 · 2023: 123 · 2022: 142 · 2021: 128 · 2020: 139 · 2019: 146 · 2018: 168 · 2017: 94
FWCI: 123.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ceritinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, progression-free survival, targeted therapy, adverse events, diarrhea, elevated liver enzymes, brain metastases, treatment safety and efficacy comparison, WHO performance status
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Sulfones, Carboplatin, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks